Resubmission of the ONS-5010 BLA targeted for Q1 CY2025; Initial commercial launches in Germany and the UK planned to commence in Q2 CY2025; and Potential for US FDA approval of ONS-5010 in Q3 CY2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Secures Funding and Board Restructures
- Outlook Therapeutics appoints Sukhtian as Chairman of the board of directors
- Outlook Therapeutics announces presentation of data from NORSE EIGHT
- Outlook Therapeutics enters into agreement for warrant inducement transaction
- Outlook Therapeutics’ ONS-5010 shown to be non-inferior to Lucentis in wet AMD